Liquid chromatography–tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma

Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology

“…One of the main reasons for the absence of metabolite quantification is the lack of commercial standards at the time of development of the assay [84]. Alternatively, papers from Vikingsson et al [133] reported quantification of the metabolites relative to their parent compound, or a related metabolite of which an analytical standard is readily available [84,132,133]. For sunitinib, it has been demonstrated that the active metabolite is equally potent, but less dermatotoxic.…”

“…TKIs [96,115,132,133,136], no recent analytical papers describing quantitative assays for these metabolites were published. Vikingsson et al described that a glucuronide and a glucosylation metabolite of vemurafenib were excluded from their method due to low concentrations and poor stability [132].…”

“…axitinib Inlyta AG013736 Renal cell carcinoma VEGFR1-3, c-KIT, PDGFR No [15,101,127] bosutinib Bosulif SKI-606 Ph+CML (Bcr-Abl) BCR-ABL, Src, Lyn, Hck No [127] cabozantinib Cabometyx, Cometriq XL184 Medullary thyroid cancer c-Met, VEGFR2 No [64,147] ceritinib Zykadia LDK378 ALK+ NSCLC ALK No [22,117] crizotinib Xalkori PF02341066 ALK-fusion NSCLC ALK, ROS1, c-Met No [32,92,133] dabrafenib Tafinlar GSK2118436 B-raf V600E mut. melanoma B-Raf-V600E No [148] dasatinib Sprycel BMS354825 Ph+CML (Bcr-Abl) BCR-ABL, PDGFR, Src, c-Kit, … No [7,15,23,31,47,62,83,95,99,114,119,124,126,130,149] erlotinib Tarceva OSI774 NSCLC EGFR, JAK2V617F No [15,23,51,61,67,84,91,105,107,114,118,124,125,128,129,135,1 50,151] gefitinib Iressa ZD1839 NSCLC EGFR No [15,52,53,107,114,124,125,152] ibrutinib Imbruvica PCI32765 MCL, CLL, WM Brutons TK (BTK) Yes, Cys481 [72,76,98,113,145] imatinib Gleevec, Glivec ST1571 Ph+CML (Bcr-Abl), GIST BCR-ABL, PDGFR, SCF, c-KIT No [7,…”

Enhanced spectrofluorimetric determination of the multitargeted tyrosine kinase inhibitor, crizotinib, in human plasma via micelle-mediated approach

“…Accordingly, reliable and accurate analytical methodology for CRZ determination is crucial for further pharmacokinetic studies. Literature review revealed that CRZ was assayed in plasma by liquid chromatography coupled with either tandem mass spectrometry [6][7][8][9] or fluorescence detection [10]. However, these chromatographic methods suffered from complexity and being expensive.…”

Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization–tandem mass spectrometry (LC-ESI–MS/MS)

“…A recent report described the first validated assay for crizotinib in mouse plasma using protein precipitation and LC–MS/MS [16], however, no validated methods have been published for use with human samples. Therefore, in this paper we describe a rapid LC-MS/MS method that was developed and validated according to internal SOP’s to assay crizotinib concentrations in both human and mouse plasma using a 96-well solid phase extraction procedure.…”